Search results for "Quinolone"

showing 10 items of 108 documents

Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin

2005

Abstract The efflux process due to p-glycoprotein-like mechanisms of ciprofloxacin (CIP) and grepafloxacin (GRX) has been studied “in situ” in rats and “in vitro” in Caco-2 cells. The results were modelled by a curve fitting procedure which allowed the characterization of the passive (Pd) and carrier mediated parameters (Vm and Km) from the raw data without initial velocities estimation. CIP absorption in rat was characterized as a passive diffusion at the assayed concentrations. Although the involvement of an efflux transporter cannot be ruled out, its relevance in the transport of the fluoroquinolone is negligible. In GRX absorption, an efflux process is implicated and it is detected in b…

MaleAbsorption (pharmacology)In situCell Membrane PermeabilityPharmaceutical ScienceModels BiologicalPiperazinesDiffusionAnti-Infective AgentsCiprofloxacinIntestine SmallmedicineAnimalsHumansRats WistarAntibacterial agentChemistryTransporterIn vitroGrepafloxacinRatsPerfusionIntestinal AbsorptionBiochemistryPermeability (electromagnetism)BiophysicsEffluxCaco-2 CellsFluoroquinolonesmedicine.drugInternational Journal of Pharmaceutics
researchProduct

Intrinsic Absolute Bioavailability Prediction in Rats Based on In Situ Absorption Rate Constants and/or In Vitro Partition Coefficients: 6‐Fluoroquin…

2000

A preliminary study attempting to predict the intrinsic absolute bioavailability of a group of antibacterial 6-fluoroquinolones-including true and imperfect homologues as well as heterologues-was carried out. The intrinsic absolute bioavailability of the test compounds, F, was assessed on permanently cannulated conscious rats by comparing the trapezoidal normalized areas under the plasma concentration-time curves obtained by intravenous and oral routes (n = 8-12). The high-performance liquid chromatography analytical methods used for plasma samples are described. Prediction of the absolute bioavailability of the compounds was based on their intrinsic rat gut in situ absorption rate constant…

MaleAbsorption (pharmacology)In situChemistryAnalytical chemistryBiological AvailabilityPharmaceutical ScienceIn vitroAbsorptionRatsBioavailabilityPartition coefficientAnti-Infective AgentsPharmacokineticsArea Under CurveAnimalsRats WistarDigestive SystemFluoroquinolonesAbsolute bioavailabilityAntibacterial agentJournal of Pharmaceutical Sciences
researchProduct

Odorant metabolism catalyzed by olfactory mucosal enzymes influences peripheral olfactory responses in rats.

2013

International audience; A large set of xenobiotic-metabolizing enzymes (XMEs), such as the cytochrome P450 monooxygenases (CYPs), esterases and transferases, are highly expressed in mammalian olfactory mucosa (OM). These enzymes are known to catalyze the biotransformation of exogenous compounds to facilitate elimination. However, the functions of these enzymes in the olfactory epithelium are not clearly understood. In addition to protecting against inhaled toxic compounds, these enzymes could also metabolize odorant molecules, and thus modify their stimulating properties or inactivate them. In the present study, we investigated the in vitro biotransformation of odorant molecules in the rat …

MaleAnatomy and Physiology[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionSensory PhysiologyEnzyme Metabolismlcsh:MedicineQuinolonesBiochemistryCarboxylesterasechemistry.chemical_compoundPentanols0302 clinical medicineCoumarinsEnzyme Inhibitorslcsh:Sciencechemistry.chemical_classification0303 health sciencesMultidisciplinaryEnzyme ClassesEsterasesSensory SystemsEnzymes3. Good healthElectrophysiologyProtein Transportmedicine.anatomical_structureBiochemistryMedicineSensory PerceptionMetabolic PathwaysResearch ArticleIsoamyl acetateBiologyNeurological SystemXenobiotics03 medical and health sciencesOlfactory mucosaOlfactory MucosaTransferasesmedicineAnimalsRats WistarBiology030304 developmental biologyOlfactory Systemlcsh:RGlycosyltransferasesCytochrome P450MonooxygenaseOlfactory PerceptionRatsMetabolismEnzymechemistryOdorantsBiocatalysisbiology.proteinlcsh:Q[SDV.AEN]Life Sciences [q-bio]/Food and NutritionOlfactory epithelium030217 neurology & neurosurgeryDrug metabolismNeuroscience
researchProduct

Antibiotic prophylaxis in patients who had undergone to prostate biopsy in between the EMA warning era: effects of fluoroquinolones in diabetic and n…

2022

Abstract Purpose To investigate the effects of different antibiotic prophylaxis regimens in patients with diabetes mellitus (DM) candidates to trans-rectal ultrasound-guided prostate biopsy (TRUSPB). Methods 143 outpatients with DM who underwent TRUSPB during the period 2018–2020 were selected from a cohort of 1150 patients in 3 different institutions. Exclusion criteria were allergies, concomitant anti-platelet therapies and uncontrolled DM. Different antibiotic prophylaxis regimens were adopted. Bacterial resistance levels to fluoroquinolones into the different communities were also collected. Univariable and multivariable binomial logistic regression analyses were used to assess the odds…

MaleAntibiotic resistanceUrologyBiopsyProstateRectumBacterial InfectionsAntibiotic ProphylaxisProstate biopsyAnti-Bacterial AgentsFluoroquinoloneAntibiotic prophylaxiDiabetes MellitusHumansAntibiotic prophylaxis; Antibiotic resistance; Fluoroquinolones; Infection; Prostate biopsyInfectionFluoroquinolonesWorld journal of urology
researchProduct

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. Methods The study presented was a retrospective analysis of 50 gastrointestinal cancer patients treated with cetuximab in combination with either FOLFIRI or FOLFOX. One cohort of 15 patients received an in-house reactive skin protocol upon development of an exanthema. A second cohort of 15 patients received a skin prophylaxis starting with the first dose of cetuximab before clinical signs of toxicity. A third historic group o…

MaleCancer ResearchColorectal cancerAdministration TopicalAdministration OralCetuximabMinocyclineGastroenterologyPeritoneal NeoplasmPeritoneal NeoplasmsGastrointestinal NeoplasmsSkinHematologyintegumentary systemCetuximabTherapy reactiveMultimodal therapyVitamin K 1General MedicineMiddle AgedCombined Modality TherapyAnti-Bacterial AgentsSurvival RateTreatment OutcomeAppendiceal NeoplasmsOncologyColonic NeoplasmsAdenocarcinomaFemaleErratumQuinolizinesFluoroquinolonesmedicine.drugmedicine.medical_specialtyPrednisoloneEGFRDetergentsAntineoplastic AgentsAdenocarcinomaAntibodies Monoclonal HumanizedDisease-Free SurvivalMetronidazoleRashInternal medicineIntestinal NeoplasmsmedicineCombined Modality TherapyHumansSurvival rateAgedRetrospective StudiesOriginal PaperRectal Neoplasmsbusiness.industryRetrospective cohort studyAntibiotic ProphylaxisExanthemamedicine.diseaseDermatologydigestive system diseasesSurgerybusinessJournal of Cancer Research and Clinical Oncology
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct

Pharmacokinetics, bioavailability and absorption of flumequine in the rat.

1999

Abstract The study demonstrates that the oral extent of bioavailability of flumequine in the rat, relative to the intravenous injection, is complete (0.94±0.04) and not significantly different from that found by the intraduodenal route (0.95±0.04). The rate of oral bioavailability, however, is slow ( k a =1.20±0.07 h −1 ; T max =2.0 h), but enough to maintain plasma levels above the minimal inhibitory concentration of the most common pathogens for an extended period of time (about 10 h). The reason for the oral absorption slowness could be a slow gastric emptying, an adsorption to the gastric mucosae, a precipitation in the gastric medium or any other feature concerning the stomach as the i…

MaleDuodenumPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalRandom AllocationPharmacokineticsAnti-Infective AgentsOral administrationEnterohepatic CirculationmedicineAnimalsRats WistarEnterohepatic circulationAntibacterial agentGastric emptyingChemistryStomachGeneral MedicineBioavailabilityRatsmedicine.anatomical_structureIntestinal AbsorptionFlumequineQuinolizinesBiotechnologymedicine.drugFluoroquinolonesEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Emergence of tularemia in France: paradigm of the Burgundy region

2011

International audience; We report three consecutive cases of tularemia occurring in Burgundy, France, a region previously considered not endemic for tularemia. The patients presented with varied and unspecific clinical manifestations. The epidemiological circumstances, especially the mode of contamination, were not particularly suggestive of tularemia. Serological diagnosis was delayed in two cases because of the lack of significant antibody titers at the time of admission. In contrast, a diagnosis could readily be obtained in all three cases by detection of Francisella tularensis DNA from clinical samples using PCR-based methods. These cases highlight the increased incidence and geographic…

MaleEpidemiologyMESH: Lymph NodesCommunicable Diseases EmergingSerologyTularemia0302 clinical medicineMESH: Early DiagnosisEpidemiologyDiagnosisMESH: Communicable Diseases Emerging030212 general & internal medicineMESH: DoxycyclineFrancisella tularensisTularemia0303 health sciencesMESH: TularemiaMESH: Middle AgedbiologyMESH: Real-Time Polymerase Chain ReactionIncidence (epidemiology)[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]Antibody titerGeneral Medicinerespiratory systemMiddle Aged3. Good healthAnti-Bacterial AgentsInfectious DiseasesFrancisella tularensis DNADoxycyclineFemaleFranceFluoroquinolonesAdultDNA BacterialMicrobiology (medical)medicine.medical_specialtyReal-Time Polymerase Chain Reactioncomplex mixtures03 medical and health sciencesMESH: Francisella tularensisMESH: Anti-Bacterial AgentsmedicineHumansFrancisella tularensisMESH: Humans030306 microbiologyMESH: AdultMESH: Fluoroquinolonesbiology.organism_classificationmedicine.diseasebacterial infections and mycosesVirologyMESH: DNA BacterialMESH: MaleMESH: FranceEarly DiagnosisbacteriaLymph NodesMESH: FemaleReal-time PCRInternational Journal of Infectious Diseases
researchProduct

Biophysical Models as an Approach To Study Passive Absorption in Drug Development: 6-Fluoroquinolones

1995

A preliminary study attempting to assess and explain the intestinal absorption of a series of antibacterial 7-piperazinyl-6-fluoroquinolones is presented. The synthesis, n-octanol partition coefficients, intrinsic rat gut in situ absorption rate constants, and in vitro antibacterial activity data found for these homologous compounds are described. A fluorimetric, reverse-phase HPLC method was performed for the quantification of the quinolones in absorption and partition samples. Equations based on two classic biophysical absorption models are given for predicting the intrinsic absorption features of the series according to the partition data or merely single structural parameters. In situ a…

MaleIn situChemical PhenomenaBiophysicsAnalytical chemistryAdministration OralPharmaceutical ScienceModels BiologicalBiophysical PhenomenaIntestinal absorptionBiopharmaceuticsAnti-Infective AgentsPharmacokineticsIn vivoComputational chemistryAnimalsPartition (number theory)Rats WistarAbsorption (electromagnetic radiation)Chromatography High Pressure LiquidBacteriaChemistry PhysicalChemistryLipidsRatsMolecular WeightPartition coefficientIntestinal AbsorptionInjections IntravenousAntibacterial activityFluoroquinolonesJournal of Pharmaceutical Sciences
researchProduct

Synthesis, configuration, and calcium modulatory properties of enantiomerically pure 5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylates.

1992

Enantiomerically pure hexahydroquinolinones of the structural type 9 were prepared by a variation of the Hantzsch synthesis in which an optically active acetoacetate served as a chiral auxiliary reagent. Determinations of the de and ee values are described. The absolute configurations of the optically pure products were characterized by single-crystal X-ray analysis. The antipodes 9a and 9b exhibited calcium antagonistic activities on smooth musculature; the (S)-(-)-enantiomer 9b was the more potent compound with regard to the EC50 values which differed by a factor of 100; the intrinsic activity of 9b was 1.2, compared with a value of 0.54 for 9a. On the other hand, R-(+)-9a exerted positiv…

MaleIntrinsic activityGuinea PigsMolecular Conformationchemistry.chemical_elementCalciumQuinolonesMedicinal chemistrychemistry.chemical_compoundX-Ray DiffractionIleumDrug DiscoveryAnimalsHeart AtriaAortaChiral auxiliaryBicyclic moleculeMolecular StructureEnantioselective synthesisAbsolute configurationBiological activityStereoisomerismPapillary MusclesAtrial FunctionCalcium Channel BlockersElectric StimulationchemistryReagentMolecular MedicineFemaleMuscle ContractionJournal of medicinal chemistry
researchProduct